Bio-Path Holdings Pre-Tax Profit Margin 2010-2024 | BPTH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Bio-Path Holdings pre-tax profit margin from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Bio-Path Holdings Pre-Tax Profit Margin 2010-2024 | BPTH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Bio-Path Holdings pre-tax profit margin from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.5B
Takeda Pharmaceutical (TAK)	$43.4B
Merck (MKKGY)	$21B
Astellas Pharma (ALPMY)	$20.3B
Sandoz Group AG (SDZNY)	$19.9B
United Therapeutics (UTHR)	$17.9B
Summit Therapeutics (SMMT)	$16.1B
Neurocrine Biosciences (NBIX)	$12.9B
Shionogi (SGIOY)	$12.3B
Catalent (CTLT)	$10.8B
Jazz Pharmaceuticals (JAZZ)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.4B
Orion OYJ (ORINY)	$6.8B
Corcept Therapeutics (CORT)	$6.2B
Ionis Pharmaceuticals (IONS)	$6.1B
Crinetics Pharmaceuticals (CRNX)	$4.8B
PTC Therapeutics (PTCT)	$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.8B
Dyne Therapeutics (DYN)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.8B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
Soleno Therapeutics (SLNO)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.2B
Recursion Pharmaceuticals (RXRX)	$2.2B
Centessa Pharmaceuticals (CNTA)	$1.9B
Harrow (HROW)	$1.8B
Evotec AG (EVO)	$1.7B
Ocular Therapeutix (OCUL)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.7B
ARS Pharmaceuticals (SPRY)	$1.7B